Rigel Pharma (RIGL) Reports In-Line Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $50.53 --0%
Revenue Growth %: +15.2%
Financial Fact:
Income (loss) from operations: -22.74M
Today's EPS Names:
ARDS, OMID, OXLC, More
Revenue Growth %: +15.2%
Financial Fact:
Income (loss) from operations: -22.74M
Today's EPS Names:
ARDS, OMID, OXLC, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q1 EPS of ($0.19), in-line with the analyst estimate of ($0.19). Revenue for the quarter came in at $5 million versus the consensus estimate of $4 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Clarivate (CLVT) Tops Q3 EPS by 3c; Offers Guidance
- Otter Tail Corp (OTTR) Misses Q3 EPS by 9c
- Leidos (LDOS) Tops Q3 EPS by 57c, Misses on Revenue; Offers FY26 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
